The idiopathic hypereosinophilic syndrome and eosinophilic leukemias.
暂无分享,去创建一个
[1] D. Metcalfe,et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. , 2004, Blood.
[2] J. Ring,et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. , 2003, The New England journal of medicine.
[3] Ricardo C T Aguiar,et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. , 2003, Blood.
[4] V. Pitini,et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. , 2003, Blood.
[5] D. Gilliland,et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. , 2003, Blood.
[6] E. Baxter,et al. Imatinib for systemic mast-cell disease , 2003, The Lancet.
[7] B. Bain. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias , 2003, British journal of haematology.
[8] D. Gilliland,et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. , 2003, Blood.
[9] M. Caligiuri,et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[10] Peter Marynen,et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.
[11] B. Bain,et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.
[12] B. Bain. An Overview of Translocation-Related Oncogenesis in the Chronic Myeloid Leukaemias , 2002, Acta Haematologica.
[13] B. Löwenberg,et al. Eosinophilia and granulocytic dysplasia terminating in acute myeloid leukaemia after 24 years , 1996, British journal of haematology.
[14] B. Bain. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. , 1996, British journal of haematology.
[15] L. Ackerman,et al. Evolution to eosinophilic leukemia with a t(5:11) translocation in a patient with idiopathic hypereosinophilic syndrome. , 1984, Cancer genetics and cytogenetics.
[16] T. Barbui,et al. Immunophenotypic evaluation of circulating T-cell clones in hypereosinophilic syndromes with or without abnormal CD3 and CD4 lymphocytes. , 2004, Haematologica.
[17] E. Ascari,et al. A further case of myeloproliferative syndrome with reciprocal translocation (8;13)(p11;q12). , 2004, Haematologica.
[18] M. Baccarani,et al. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. , 2004, Haematologica.
[19] G. L. Gattuta,et al. Imatinib treatment–induced cardiomyopathy in hypereosinophilic syndrome , 2003 .
[20] F. Roufosse,et al. Idiopathic eosinophilia. , 2000, New England Journal of Medicine.
[21] R. Dummer,et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. , 1999, The New England journal of medicine.
[22] S. Wolff,et al. The hypereosinophilic syndrome , 1975 .